Company news
Ocugen, Inc. (NASDAQ:OCGN) news
Ocugen, Inc. news releases on 6ix. Latest, Oct 6, 2026: Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Press releases & updates
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
October 6, 2026
Ocugen to Participate in Upcoming Scientific Conferences
September 29, 2026
Ocugen to Participate in Upcoming Scientific Conferences
September 30, 2026
Ocugen to Participate in Upcoming October Investor and Industry Conferences
September 28, 2026
Ocugen to Participate in Upcoming October Investor and Industry Conferences
September 29, 2026
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
September 25, 2026
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
September 1, 2026
Ocugen to Participate in Upcoming September Investor and Industry Conferences
August 25, 2026
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
August 6, 2026
Ocugen to Participate in Upcoming August Investor Conferences
July 31, 2026
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
July 30, 2026
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
July 29, 2026
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
July 28, 2026
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
July 13, 2026
Ocugen to Participate in Upcoming June Investor and Industry Conferences
June 2, 2026
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
May 14, 2026
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
May 13, 2026
Ocugen Provides Business Update with First Quarter 2026 Financial Results
May 5, 2026
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
May 5, 2026
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
May 4, 2026
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
April 29, 2026
Ocugen to Present at April 2026 Investor and Industry Conferences
April 23, 2026
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
March 31, 2026
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
March 23, 2026
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
March 22, 2026
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
March 2, 2026
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
February 18, 2026
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
February 9, 2026
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
January 22, 2026
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
January 21, 2026
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
January 15, 2026
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
January 12, 2026
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
January 12, 2026
Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
January 9, 2026
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
December 9, 2025
Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
November 19, 2025
Ocugen Provides Business Update with Third Quarter 2025 Financial Results
November 4, 2025
Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
October 22, 2025
Ocugen to Present at Industry and Investor Conferences in October 2025
October 1, 2025
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
September 14, 2025
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
September 1, 2025
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
August 12, 2025
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
August 11, 2025
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
August 7, 2025
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
July 31, 2025
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
July 20, 2025
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
July 17, 2025
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
July 16, 2025
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
June 22, 2025